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Abstract—Objective: Identifying mild cognitive impairment
(MCI) subjects who will progress to Alzheimer’s disease is not
only crucial in clinical practice, but also has a significant potential
to enrich clinical trials. The purpose of this study is to develop
an effective biomarker for an accurate prediction of MCI-to-AD
conversion from magnetic resonance (MR) images.
Methods: We propose a novel grading biomarker for the
prediction of MCI-to-AD conversion. First, we comprehensively
study the effects of several important factors on the perfor-
mance in the prediction task including registration accuracy, age
correction, feature selection and the selection of training data.
Based on the studies of these factors, a grading biomarker is
then calculated for each MCI subject using sparse representation
techniques. Finally, the grading biomarker is combined with age
and cognitive measures to provide a more accurate prediction of
MCI-to-AD conversion.
Results: Using the ADNI dataset, the proposed global grad-
ing biomarker achieved an area under the receiver operating
characteristic curve (AUC) in the range of 79%-81% for the
prediction of MCI-to-AD conversion within 3 years in 10-fold
cross validations. The classification AUC further increases to
84%-92% when age and cognitive measures are combined with
the proposed grading biomarker.
Conclusion: The obtained accuracy of the proposed biomarker
benefits from the contributions of different factors: a tradeoff
registration level to align images to the template space; the
removal of the normal aging effect; selection of discriminative
voxels; the calculation of the grading biomarker using AD and
normal control groups; the integration of sparse representation
technique and the combination of cognitive measures.
Significance: The evaluation on the ADNI dataset shows the
efficacy of the proposed biomarker and demonstrates a significant
contribution in accurate prediction of MCI-to-AD conversion.
Index Terms—structural MR imaging, biomarker, prediction
of MCI conversion, machine learning, Alzheimer’s disease
I. INTRODUCTION
Studies have shown that individuals with mild cognitive
impairment (MCI) progress to Alzheimer’s disease (AD) at
a rate of 10% to 15% per year [1]. In the clinical context,
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it is particularly interesting to predict whether a subject with
MCI will go on to develop AD or not within a given time
period (i.e. 3 years) as early diagnosis would allow doctors
to treat patients sooner so that potential disease-modifying
therapies could be tested and applied. Although no drug or
treatment has so far been reported to be able to stop the
progress of AD, there are some medications that can delay
the onset of some symptoms such as memory loss, confusion,
and cognitive problems [2]. In addition, the early diagnosis
is also helpful for selecting suitable patients for clinical trials.
Numerous studies [3], [4], [5], [6], [7], [8], [9], [10], [11], [12],
[13], [14], [15], [16], [17], [18], [19], [20] use neuroimaging
techniques to detect pathology associated with AD and to
predict the MCI-to-AD conversion. Among them, structural
magnetic resonance imaging (MRI) has been the most exten-
sively used imaging modality in the detection and prediction
of AD as it is widely available and offers good diagnostic
accuracy with moderate costs. In addition, MRI shows high
correlation with the progression from MCI to AD [21]. How-
ever, the pathological variations between stable MCI (SMCI)
and progressive MCI (PMCI) that can be detected by MRI
are subtle. This subtle difference is also accompanied with
large inter-subject variability and age-related changes, which
makes the MRI-based prediction of MCI-to-AD conversion
a challenging task. In a recent comprehensive study [22], ten
methods were evaluated for the MRI-based prediction of MCI-
to-AD conversion and only four methods could discriminate
between SMCI and PMCI more accurately than a random
classifier. Therefore, it is essential to develop more advanced
methods for the prediction of MCI-to-AD conversion.
In order to reduce the large inter-subject variability, MR
images are usually spatially registered to a common space
for comparison [14], [20], [23]. Different studies have used
different registration techniques to align anatomies at different
levels of detail. For example, affine registration was used in
[23] while more accurate nonrigid registrations were utilized
in other studies [14]. In [22], the registration in SPM5 was
compared to the more accurate registration method DARTEL.
The use of DARTEL was shown to significantly improve the
classification results [22]. Although accurate registration can
successfully align anatomical structures in different subjects
for comparison, the pathological changes between groups may
be partially removed at the same time. At the extreme where
no registration is performed, the inter-subject variability and
the pathological changes between groups are fully preserved.
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However, large inter-subject variability may conceal the more
subtle pathological variations, hampering the classification of
MCI subjects. At the other extreme where registration is near
perfect, inter-subject variability and pathological changes are
both removed. Thus, there is a tradeoff between the level
of image alignment that removes uninteresting inter-subject
variability and the amount of detectable pathological changes,
which would still allow the measurement of group differences
for classification.
The group differences are not only affected by pathological
changes and inter-subject variability, but also influenced by
the changes associated with aging. Since the normal aging can
result in atrophy on the brain, it can be similar to the atrophies
caused by AD. This adds confounding effects in using the
disease-specific changes for classification. In previous studies,
age has been demonstrated as an important feature in either
detecting AD [23] or predicting MCI-to-AD conversion [13]
because it is a risk factor for AD. Therefore, it may be helpful
to remove the effect of normal aging from MRI data before
training the classifiers. For example, in a recent challenge [24],
eight out of fifteen teams incorporated aging effects in their al-
gorithms for the classification of AD, where the normal aging
effect was eliminated using age-dependent normalization [24]
or regression [20], [24]. The removal of effects associated with
normal aging has been reported to improve the classification
performance significantly [20], [25] or slightly [22] depending
on the adopted features and classification methods.
In addition to the effect of registration and normal aging, the
use of training data from different groups of subjects can also
influence the prediction of MCI-to-AD conversion. Since the
population of MCI subjects is highly heterogeneous, previous
studies [14], [20], [23], [26], [27], [28] have shown that the
inclusion of AD and normal controls (NC) subjects can be
beneficial for the classification between SMCI and PMCI.
A semi-supervised learning method [20], [27] was used to
integrate information from AD and NC subject to augment
the prediction of MCI-to-AD conversion. Auxiliary data from
AD and NC subjects were used in a domain transfer learning
method [28] to aid the classification of MCI subjects. In [14],
classifiers learned for separating AD and NC subjects were
directly used to distinguish between SMCI and PMCI. In
[23], new biomarkers were derived by propagating disease
information from AD and NC subjects to MCI subjects.
Another important factor for the prediction of MCI-to-AD
conversion is feature selection. The number of available voxel-
wise features (1,827,095 after preprocessing) in the whole
brain is very large, but many of these features may not be
related to pathological change due to AD. Therefore, feature
selection is an essential step to select the most informative
and revelant features for training effective classifiers. Statis-
tical methods such as t-tests or wrapper-based methods such
as the support vector machine recursive feature elimination
(SVM-RFE) are commonly used approaches for selecting
features. More recently, sparse regression techniques have
been utilized to select discriminative features for analysis. For
example, LASSO regression that incorporates an L1 penalty
to encourage a sparse solution has been applied to identify
important voxels in the brain that are related to pathological
changes of AD in [29]. However, the selected voxels are
randomly distributed over the whole brain, which is difficult
for interpretation. More advanced sparse regression methods
such as Elastic Net [30] or tree structured sparse learning [29]
were proposed to integrate the spatial structure in the images
into the feature selection process so that more interpretable
results can be generated. In another recent work [31], group
sparse regression method has been utilized to select the
multimodel features by considering the intrinsic relatedness
between features across different modalities.
In this paper, we will first study the impact of the above
four different factors: registration accuracy, age correction,
selection of training data and features. Based on the obser-
vation of the impact of these factors, we further propose a
novel biomarker which we refer to as global grading for the
prediction of MCI-to-AD conversion. The proposed grading
biomarker benefits from the studies of these factors. To cal-
culate the grading biomarker, MR images are first aligned to
the template space using well controlled registration. Then, the
normal aging effect is removed from the image intensities by
using a linear regression model. After that, a feature selection
step is carried out to select voxels that can characterize the
atrophy associated with AD. Finally, a global grading value is
calculated for each MCI subject by utilizing the selected voxels
and the disease information of AD and NC subjects. The
main novelties of the proposed MR-based grading biomarker
are: (1) a well controlled registration accuracy to align MR
images to a template space for comparison; (2) the removal of
confounding effects associated with aging; (3) a robust feature
selection step which is performed on discriminating NC versus
AD, thus eliminating the use of MCI subjects in the feature
selection step, and (4) the propagation of disease information
from NC and AD subjects to MCI subjects using sparse
representation technique. The classification performance of the
proposed biomarker was validated on the standardized list [32]
of baseline scans from the Alzheimer’s Disease Neuroimaging
Initiative (ADNI) and compared with those of other state-
of-the-art methods [20], [22], [33] on the same datasets.
Furthermore, the proposed grading biomarker is combined
with cognitive measures to gain further improvements in the
prediction of MCI-to-AD conversion.
II. MATERIAL AND METHODS
A. ADNI Dataset
Data used in the preparation of this article were obtained
from the ADNI database (adni.loni.ucla.edu). The ADNI was
launched in 2003 by the National Institute on Aging (NIA), the
National Institute of Biomedical Imaging and Bioengineering
(NIBIB), the Food and Drug Administration (FDA), private
pharmaceutical companies and non-profit organizations, as a
$60 million, 5-year public-private partnership. The primary
goal of ADNI has been to test whether serial MRI, PET,
other biological markers, and clinical and neuropsychological
assessment can be combined to measure the progression of
MCI and early AD. Determination of sensitive and specific
markers of very early AD progression is intended to aid
researchers and clinicians to develop new treatments and
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monitor their effectiveness, as well as lessen the time and cost
of clinical trials.
The standardized list of baseline scans from ADNI-1 [32]
was utilized in our work to enable future comparisons with
other methods. The standardized list consists of 818 subjects
that were classified into five different groups as shown in
Table I. The AD and NC groups were determined according
to the diagnosis at baseline. Subjects in the MCI group were
classified as PMCI if the subjects converted to AD during
a 3 year follow-up. Subjects were classified as SMCI if the
diagnosis was MCI at both baseline and 36 months. Those
whose diagnosis were missing at 36 months were grouped as
unknow MCI (uMCI). The uMCI subjects were not used in
the validation.
B. Image Preprocessing
The framework of the proposed classification method is
illustrated in Figure 1, consisting of five steps in the prepro-
cessing stage. T1-weighted Magnetic Resonance (MR) brain
images were first preprocessed by the standard ADNI pipeline
as described in [34], and skull-stripped using the method
proposed in [35]. In order to investigate the effect of registra-
tion on the prediction of MCI-to-AD conversion, all images
were aligned to the MNI152 template using registration based
on B-spline free-form deformation (FFD) [36]. Five different
levels of deformation were used: affine, 20mm, 10mm, 5mm,
2.5mm (from coarse to fine registration), generating images
in the MNI152 template space with different alignment levels.
Except for the affine registration, non-rigid were performed
using B-spline FFD with the above varying control point
spacings. It should be mentioned that if more accuate registra-
tion is applied, the images are better aligned for comparison
while at the same time more pathological changes might be
removed. Additionally, the approach proposed in [37] was used
to normalize the image intensities between the subjects and the
template. The basic idea in [37] is to deform the histogram
of a given image to match a standard histogram. In our
work, we used the histogram of the MNI152 template image
as the standard histogram. After registration and intensity
normalization, all the images were in the same template
space and had the same intensity scale for comparison. Then,
the normalized intensities in the images can be extracted as
features for classification.
The effects of normal aging were then estimated on the
voxel-wise intensities of NC subjects by fitting a linear re-
gression model [25] at each location. Given that there are
N healthy subjects and each image contains M brain vox-
els, the normalized intensity values of the preprocessed MR
images of all NC subjects can be represented by a matrix
XT = [X1
T , X2
T , · · · , XiT , · · · , XMT ] ∈ RN×M , where
each row is given as Xi = [xi1, xi2, · · · , xiN ] ∈ R1×N , i =
1, 2, · · · ,M . The ages of N healthy subjects are denoted as
a vector A ∈ R1×N . The effect of age-related atrophy is
estimated at each voxel separately by fitting a linear regression
model Xi = wiA+ bi. After this model is solved in the least
squares sense, the aging effect at the ith voxel of the jth image
can be removed as xnewij = xij − wiaj − bi. Figure 2 shows
an example of the images after different preprocessed steps.
(a) (b) (c)
Fig. 2. Images after different preprocessing steps: (a) image after skull-
stripping; (b) image after spatially and intensity normalization (left) and the
MNI152 template (right); (c) image after the removal of normal aging effect.
C. Feature Selection
After preprocessing, there is still a large amount of voxels
available in brain MR images, but not all of them are related
to the pathological changes specific to AD. In addition, the
number of available images is typically much smaller than the
number of voxels, which could result in classifier overfitting.
Therefore, a feature selection step is necessary to tackle this
problem and also to select informative voxels for classification.
Sparse regression techniques have been widely used to select
discriminative voxels for AD classification in previous works
[29], [30]. The LASSO method using L1 norm [29] is one
of the effective sparse regression methods. However, there
are two drawbacks of the original LASSO sparse regression
[38]: (a) the structural relationship of neighboring voxels are
ignored; (b) the number of selected voxels is limited by
the number of images. In order to address these drawbacks,
advanced sparse regression methods [29], [30], [31] have
been recently proposed for selecting discriminative voxels. For
example, manifold learning techniques [31] have been suc-
cessfully incorporated into the sparse feature selection models
to aid the classification. Furthermore, some studies [39], [40]
proposed methods of joint sparse feature selection for both
disease diagnosis and clinical score prediction. Although these
advanced methods [31], [39], [40] provide a good solution
for selecting meaningful features, they were applied to select
features from hundreds of region-wise features. When feature
selection is performed over millions of voxel-wise features,
these advanced methods might not be implemented efficiently.
In this work, we utilized an Elastic Net (EN) method [30] for
feature selection as this method can still be solved efficiently
even with an input of millions of features. It is formulated as
follows:
βˆ = min
β
1
2
‖y −Xβ‖22 + λs‖β‖1 + λg ‖β‖22 (1)
where X is a matrix containing vectorized training images and
y includes the clinical labels of these images. The EN method
adds a L2 regularization term to the LASSO regression, which
results in a grouping effect to select highly correlated variables
(i.e. neighboring voxels) and allows us to select a number of
voxels greater than the number of images. Equation 1 can be
solved efficiently when λg →∞. As shown in [41], a closed-
form solution of minimizing Equation 1 can then be obtained
for each variable xi:
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TABLE I
DEMOGRAPHIC INFORMATION OF THE DATASET USED IN THIS STUDY. MMSE: MINI-MENTAL STATE EXAMINATION; CDR-SB: CLINICAL DEMENTIA
RATING-SUM OF BOXES; RAVLT: REY’S AUDITORY VERBAL LEARNING TEST; FAQ: FUNCTIONAL ACTIVITIES QUESTIONNAIRE; ADAS-COG:
ALZHEIMER’S DISEASE ASSESSMENT SCALE-COGNITIVE SUBTEST.
Group Number Age MMSE CDR-SB RAVLT FAQ ADAS-cog
NC 229 75.9 ± 5.0 29.1 ± 1.0 0.03 ± 0.12 42.9 ± 10.0 0.14 ± 0.60 6.20 ± 2.91
SMCI 129 74.6 ± 7.5 27.6 ± 1.7 1.34 ± 0.65 35.1 ± 10.2 2.03 ± 3.08 9.65 ± 4.11
PMCI 171 74.5 ± 7.0 26.6 ± 1.7 1.88 ± 0.97 27.1 ± 6.2 5.61 ± 5.11 13.20 ± 4.03
uMCI 98 75.2 ± 8.0 27.0 ± 1.9 1.48 ± 0.87 31.3 ± 9.1 3.08 ± 3.73 11.03 ± 4.39
AD 191 75.3 ± 7.5 23.3 ± 2.0 4.31 ± 1.63 22.9 ± 8.1 13.03 ± 6.85 18.55 ± 6.45
Fig. 1. The framework of the proposed method. The influence of different steps (in orange color) including registration, age correction, feature selection and
training groups are studied. Based on the analysis of the impact of these factors, a novel grading biomarker is then proposed for the prediction of MCI-to-AD
conversion. The same pre-processing step is applied to all images before calculating the grading biomarker.
βˆi
λg→∞
=
(∣∣yTxi∣∣− λs
2
)
+
sgn
(
yTxi
)
, i = 1, 2, . . . ,M
(2)
where (v)+ = max(v, 0) refers to the positive part. Equation
(2) is known as a univariate soft thresholding problem and
can be solved very efficiently since yTxi is the univariate
regression coefficient. Most existing approaches perform the
feature selection by just using the data from MCI subjects.
However, in a recent study [20], it was shown that the
feature selection using data from AD and NC subjects could
significantly improve the prediction accuracy of MCI-to-AD
conversion. Here, we applied the EN method on images of
AD and NC subjects for determining discriminative voxels.
Another benefit from using AD and NC subjects for feature
selection is that we can avoid the double-dipping problem. The
approach that uses the same dataset for selection and selective
analysis is referred to as double dipping [42]. For example,
if the test data are involved in both the feature selection
and the subsequent classifier validation, it will result in the
double-dipping problem. Classification methods should avoid
double dipping in order to perform a fair validation. In our
work, only AD and NC subjects are used for feature selection,
avoiding the use of the information from MCI subjects. Thus,
our approach does not have this problem. In addition, a re-
sampling scheme [30] was employed to reduce sampling bias
and to enable a robust feature selection. This scheme selects
discriminative voxels by repeatedly fitting the EN regression
model on a random subset of the training images while keeping
track of voxels that are consistently selected in the sparse
regression model. Figure 3 shows three orthogonal views of
the probabilistic mask obtained from the EN algorithm using
non-rigid registration with a 10mm control point spacing.
Fig. 3. Orthogonal views of the probability mask for the selection of
discriminative voxels.
D. Calculation of Global Grading Biomaker
One aim in this work is to develop a biomarker for the
prediction of MCI-to-AD conversion by utilizing the informa-
tion from AD and NC subjects. As shown in many studies
[14], [20], [23], [28], the disease information of AD and
NC subjects are helpful for separating PMCI and SMCI.
The hypothesis justifying this is that the subjects with SMCI
are more NC-like while subjects who go on to develop
dementia are more AD-like. The classification of AD vs NC
is a simplified version of the classification between PMCI
and SMCI. Since the population of MCI subjects is highly
heterogeneous, training classfier for AD vs NC might be
more effective than training classifier for PMCI vs SMCI.
Here, we develop a novel biomarker by propagating disease
labels of NC and AD subjects to MCI subjects. A global
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grading value is calculated for each MCI subject and used as
biomarker for classification. Given the NC and AD subjects as
the training population, the relationship between the training
population and each MCI subject needs to be investigated so
that the disease information of the training population can be
propagated to MCI subjects. In [23], the relationship between
each MCI subject and the training population is modeled by a
weighting function. Here, we model this relationship using a
sparse representation method, which has been demonstrated to
be superior to the weighting function in image segmentation
[43], [44]. Each MCI subject is assumed to lie in the space of
the training population, which means that it can be represented
by a linear combination of NC and AD subjects in the training
population. In addition, a sparse constraint is added to the
representation. In order to seek a sparse representation of
each MCI subject, we also use the Elastic Net technique.
After feature selection, K discriminative voxels are determined
and K intensity values are extracted from each image. Given
XADNC ∈ RK×N that contains the intensity values of N
training images and XMCI ∈ RK×1 that contains the intensity
values of a single MCI image, the sparse representation of this
MCI subject can be obtained by minimizing the following cost
function:
αˆ = min
α
1
2
∥∥XMCI −XADNCα∥∥2
2
+λ1‖α‖1+λ2 ‖α‖22 (3)
Here αˆ are the coding coefficients. Most of the coefficients in
αˆ are zero due to the sparsity constraint. If the coefficient in αˆ
is not zero, it indicates that the corresponding training image
has been selected to propagate its clinical label information
to the target MCI subject. By adding L2 norm in Equation
(3), a grouping effect can be obtained over the sparse coding
coefficients. Qualitatively speaking, an algorithm exhibits the
grouping effect if the coding coefficients of a group of highly
correlated subjects tend to be equal. For example, there are
two training subjects with very similar or identical intensity
patterns. If we just use L1 norm, it will select one of them
while eliminating the other one. However, in calculating the
grading biomarker, both subjects are similar to the target sub-
ject and should be used to propagate their disease information
to the target subject. After adding L2 norm as in equation
(3), both subjects can be selected in calculating the grading
biomarker. After the sparse solution is obtained, the scoring
of the target MCI subject is based on the coding coefficients
αˆ and the clinical status of the selected training population.
The clinical status of a training image is denoted as sj . If the
training image is a NC subject, sj is set to 1; otherwise, sj
is set to −1 for AD subjects. A global grading value of the
target MCI subject is then calculated by:
gMCI =
∑N
j=1 αˆ(j)sj∑N
j=1 αˆ(j)
(4)
where N is the number of the training images in XADNC and
αˆ(j) is the coding coefficient corresponding to the training
image XADNC(j). If gMCI is close to −1, it indicates that
this MCI subject is more characteristic of PMCI than SMCI
and is likely to convert to AD within the given time period.
If gMCI is close to 1, it indicates that the MCI subject will
possibly not convert to AD and remain stable within the given
time period.
E. Implementation details
For training classifiers with single type of features (i.e.
intensity features or grading biomarkers), support vector ma-
chine (SVM) with a linear kernel was used as SVM is one of
the most widely used classifiers. The implementation of SVM
was performed using liblinear in matlab (http://www.csie.ntu.
edu.tw/∼cjlin/liblinear). The liblinear was used since it can be
implemented efficiently for large-scale linear classification. It
is a large-scale classification problem when millions of voxel-
wise intensity features are used for the input of classifier train-
ing. The linear SVM only has one soft margin parameter C,
which was optimized in the range of 2i, i = {−5,−4, · · · , 5}
via cross validation. All features were normalized to have
zero mean and unit variance before the classification. For
calculating the grading biomarker, the parameters λ1 and
λ2 in Equation 3 were determined on the logarithmic scale
10i, i = {−3,−2, · · · , 3}. The best setting found is λ1 = 0.1
and λ2 = 100, which was used for the final calculation
of grading features. The sparse coding process of EN was
carried out using the SPAMS toolbox (http://spams-devel.
gforge.inria.fr/index.htm) [45]. For the evaluation of classi-
fication performance, 10-fold cross validation was carried out.
The reported results in terms of accuracy (ACC), sensitivity
(SEN), specificity (SPE) and area under curve (AUC) are
averages over 100 runs. To assess the statistical significance
of different results, Student’s t-tests were performed using the
accuracies of the 100 runs. In addition, in order to allow for
a fair comparison with the best result reported in [20], we
combined the proposed global grading biomarker with age
and cognitive measures for classification. The random forest
classifier (http://code.google.com/p/randomforest-matlab) was
then trained using the combined biomarkers as in [20]. The
random forest classifier was utilized because it was shown to
yield better performance than SVM for combining different
types of biomarkers [20]. Therefore, when the input was
an individual type of features, SVM was used for classifier
training while random forest was only used in combining of
different types of features.
III. RESULTS
A. The impact of registration and age correction
Experiments were conducted to investigate the effect of
registration and age correction on the prediction of MCI-to-AD
conversion. Since AD and NC subjects were used as training
images in the following feature selection step, the impact of
registration and age correction were also analysed for the
classification of AD vs NC. As can be seen from Figures
4 and 5, the SVM classifiers achieve the best accuracies
using registration with a control point spacing between 5mm
and 10mm in both classification scenarios, which can be a
good choice for the classification of AD using MR intensities.
In addition, Figure 4 shows that the removal of the age-
related effects is significantly helpful for the classification
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of AD vs NC at all registration levels. However, only slight
improvements were obtained on the classification of PMCI vs
SMCI after aging correction as shown in Figure 5. This is due
to the fact that the normal aging effect was estimated on the
NC subjects. The estimated effect is biased to the NC group.
Thus, the classification of AD vs NC can benefit more from
the removal of aging effect than the classification of PMCI vs
SMCI.
(a)
(b)
Fig. 4. Results of AD vs NC using different registration levels: (a) classifi-
cation accuracy; (b) AUC. All the evaluations used normalized intensities as
features. The beanplots show the classification results of 100 runs of 10-fold
cross validation. SVM was used for training classifiers.
To visually check the impact of registration, we compared
the group difference between AD and NC at the same location
in the MNI152 template space using t-tests. The p-values
were adjusted using the positive false discovery rate method
as described in [46]. The adjusted p-value maps at different
registration levels are shown in Figure 6. Visually, statistical
differences between AD and NC in terms of p-values become
significant but also gradually disappear in the temporal lobes
as more accurate registration was applied. Specifically, if only
affine registration is used, all the p-values are in the red or
yellow region of the color bar as shown in Figure 6, which
could result from both the inter-subject variability and the
pathological changes. However, the inter-subject variability
at this registration level may contribute much more to the
statistical differences than the pathological changes as the
anatomies are not aligned well for comparison by just using
(a)
(b)
Fig. 5. Results of PMCI vs SMCI using different registration levels:
(a) classification accuracy; (b) AUC. All the evaluations used normalized
intensities as features. The beanplots show the classification result of 100
runs of 10-fold cross validation. SVM was used for training classifiers.
affine registration. In addition, we observed that the highest
discriminative power in the ventricle region was detected
using non-rigid registration with a 20mm control point spacing
while the most significant differences in the hippocampus
was detected using registration with a control point spacing
between 5mm and 10mm. Although less discriminative voxels
were found using registration with a 2.5mm control point
spacing than that using registration with a 5mm or 10mm
control point spacing, the remaining discriminative voxels at
this registration level still allow the measurement of group
differences for classification. This is confirmed by our clas-
sification results as shown in Figures 4 and 5. Overall, the
registration with a control point spacing between 5mm and
10mm provides a tradeoff between removing the inter-subject
variability and keeping the detectable pathological difference
for classification. In addition, it should be mentioned that
most of the features selected using Equation (1) are in the
low p-value region as shown in Figure 6. However, there are
also some differences between the two spatial distributions.
This is due to the fact that the p-value maps in Figure 6
were calculated using t-tests while the feature selection was
performed using more advanced sparse regression method.
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Fig. 6. Visualization of the impact of registration. The presented results were
obtained on 191 AD vs 229 NC using t-tests. The normalized intensities after
age correction were used for comparison. Only the p-values lower than 10−2
are displayed. The showed overlay values are the log base 10 of p-values.
The hippocampus area is enlarged for visualization. The lower p values (i.e
as shown in blue) represent more significant differences between AD patients
and healthy subjects, indicating possible disease changes due to AD in that
region (i.e the blue region).
B. The importance of feature selection and training data
selection
The performance of the EN feature selection was further
evaluated for the classification of PMCI vs SMCI. We also
performed feature selection on AD and NC subjects. The
intuition behind this is that the pathological changes from
NC to AD should cover the pathological changes from SMCI
to PMCI. Thus, we assumed that the features selected from
discriminating NC vs AD would be useful for the classification
between PMCI and SMCI. As shown in Table II, the improve-
ment of using the EN feature selection was the most significant
at the registration level with a control spacing of 10mm, but the
feature selection is not consistently helpful at all registration
levels. In addition, the feature selection performed over AD
and NC subjects are more effective than that performed over
MCI subjects.
Moreover, the influence of using different data for training
classifiers was also studied. We performed both the feature
selection and the classifier training on AD vs NC and then
applied the learned classifier for discriminating PMCI vs
SMCI. The results are shown in Table II. It is interesting to
TABLE II
CLASSIFICATION RESULTS OF PMCI VS SMCI. INTENSITIES WERE USED
AS FEATURES. SVM WAS USED FOR TRAINING CLASSIFIERS. THE
METHOD MCI MCI REPRESENTS THAT THE CLASSIFIERS WERE TRAINED
ON THE MCI SUBJECTS WITHOUT FEATURE SELECTION. THE METHOD
MCIEN MCI MEANS THAT BOTH THE FEATURE SELECTION USING EN
AND CLASSIFIER TRAINING USING SVM WERE PERFORMED ON MCI
SUBJECTS. THE METHOD ADNCEN MCI REPRESENTS THAT THE
FEATURE SELECTION WAS PERFORMED ON AD VS NC WHILE THE
CLASSIFIER TRAINING WAS CARRIED OUT ON MCI SUBJECTS.
ADNCEN ADNC REPRESENTS THAT BOTH THE FEATURE SELECTION
AND CLASSIFIER TRAINING WERE PERFORMED ON AD VS NC.
Method Registraionlevel Affine 20mm 10mm 5mm 2.5mm
MCI MCI ACC (%) 63.1 63.7 66.5 66.7 65.9AUC (%) 68.3 69.2 72.8 74.0 73.2
MCIEN MCI ACC (%) 62.0 63.8 69.1 66.9 64.8AUC (%) 67.1 69.0 75.8 73.1 72.7
ADNCEN MCI ACC (%) 63.4 65.2 69.2 67.9 66.0AUC (%) 69.0 69.7 76.5 75.3 71.6
ADNCEN ADNC ACC (%) 66.7 70.0 73.2 72.4 71.7AUC (%) 70.8 74.2 78.2 76.5 76.3
note that the use of AD and NC subjects in training classifier
can significantly improve the classification accuracy and the
improvement is consistently at all registration levels.
C. Grading biomarker
Based on the selected voxels using EN, the disease informa-
tion of AD and NC subjects were then propagated to MCI sub-
jects to calculate the global grading biomarkers as described
in section II-D. In this way, we can avoid training classifiers
on AD vs NC but still use the disease information from AD
and NC subjects to aid the classification of PMCI vs SMCI
due to the propagation process. The proposed global grading
biomarker was also evaluated using different levels of registra-
tion. In addition, the hippocampus grading biomarker proposed
in [23] was calculated for comparison. In order to calculate
the hippocampus grading biomarker at different registration
levels, several steps were carried out: (1) the hippocampus was
segmented in native space using the method described in [47].
In this method, 30 atlases were transformed to a target image
space using non-rigid registration [36]. Then, atlas label maps
were transformed using the obtained transformations. Finally,
a label fusion step with an expectation-maximization (EM)
refinement was conducted to obtain a consensus segmentation.
The detailed parameter settings of this approach can be found
in [47]. (2) the segmented hippocampus was transformed
to the template space using different levels of registration;
(3) the clinical labels were propagated from NC and AD
subjects to MCI subjects at voxel level using patches [47];
(4) average grading value within the hippocampus, which we
term the hippocampus grading, was calculated for each MCI
subject. Figure 7 shows that the classification results using the
proposed global grading are more accurate than those using
the hippocampus grading. The improvement is hypothesized to
be due to the feature selection using EN and the propagation
of disease information at image level.
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Fig. 7. Comparison of the classification results using the global grading
biomarker and the hippocampus (local) grading biomarker at different reg-
istration levels. 100 runs of 10-fold cross validation were carried out. SVM
was used for training classifiers.
TABLE III
COMPARISON OF CLASSIFICATION RESULTS OF PMCI VS SMCI WITH THE
ADNI SUBSET USED BY [22]. BACC REPRESENTS BALANCED ACCURACY,
WHICH IS CALCULATED AS THE AVERAGE OF SENSITIVE AND SPECIFICITY.
Method Classifier SEN SPE AUC BACC
Voxel-COMPARE in [22] SVM 62% 67% - 65%
Voxel-STAND in [22] SVM 57% 78% - 67%
Hippo-Volume in [22] Parzen 62% 69% - 66%
Thickness-Direct in [22] SVM 32% 91% - 62%
All biomarkers in [33] LDA 69% 54% - 62%
MRI biomarker in [20] SVM 64% 72% 75% 68%
Aggrerate biomarker in [20] RF 40% 94% 81% 67%
Proposed global grading biomarker SVM 86.5% 67.2% 79.0% 76.9%
Proposed combined biomarkers RF 85.2% 71.8% 83.8% 78.5%
D. Comparison with state-of-the-art methods
In this study, we evaluated the proposed method with the
same data as used by [20] and [22] respectively. The data
from these studies was released and are also subsets of
the standardized set [32]. The same cross validations as in
[20] and [22] were used for fair comparisons. The global
grading biomarker was calculated using registration with a
control point spacing of 10mm. In addition, the global grading
biomarker was combined with age and cognitive measures
for classification (including MMSE, CDR-SB, RAVLT, FAQ
and ADAS-cog as shown in Table I), resulting in what we
call the combined biomarkers. This was performed as it has
been previously demonstrated to aid the classification of MCI
subjects [20]. In order to ensure a fair comparison with [20],
the random forest classifier [20] was used to integrate age
and cognitive measures for classification. Different measures
of the same subject were concatenated into a feature vector
for training. Tables III and IV show that our proposed method
achieves competitive performance with these state-of-the-art
methods. Based on the dataset used in [22], only four out of ten
methods can predict conversion slightly more accurately than
a random classifier as shown in Table III but none of them ob-
tained significantly better results. The obtained accuracy of our
proposed method is 76.1% with an AUC of 83.8%, which is
much higher than that of a random classifier. To the best of our
knowledge, the study in [20] reported the highest classification
performance on the prediction of MCI-to-AD conversion to
TABLE IV
COMPARISON OF CLASSIFICATION RESULTS OF PMCI VS SMCI WITH THE
ADNI SUBSET USED BY [20].
Method Classifier ACC SEN SPE AUC
MRI biomarker in [20] SVM 74.7% 88.9% 51.6% 76.6%
Proprosed global grading biomarker SVM 78.9% 76.0% 82.9% 81.3%
Aggrerate biomarker in [20] RF 81.7% 86.7% 73.6% 90.2%
Proposed combined biomarkers RF 84.1% 88.7% 76.5% 91.7%
date. In addition, to enable future comparisons with other
methods, we have provided the evaluation script (including
image list, features and cross-validation source codes available
at http://scholar.harvard.edu/ttong/software/novel-grading) to
reproduce the best result reported in this paper.
IV. DISCUSSION
Fig. 8. The classification results of PMCI vs SMCI by adding different factors
one by one. SVM was used for training classifiers. ** means that the result is
significantly improved by adding this factor. Original means that the results
were obtained by using normalized intensities after affine registration. There
is only one accuracy for the fifth column because the classifier was trained
on discriminating AD vs NC and then directly applied on the classification
of PMCI vs SMCI. Thus, there is no cross validation in this scenario. For the
sixth column, cross validations were applied to all MCI subjects using their
grading biomarkers as input features while the combined biomarkers were
used in the seventh column.
In this study, we have developed a novel grading biomarker
for the prediction of MCI-to-AD conversion. First, we investi-
gated the impact of several important factors on the prediction
performance including registration accuracy, age correction,
feature selection and the selection of training data. By adding
or optimizing these preprocessing steps, the classification
accuracy between SMCI and PMCI can be gradually improved
from 62% to 73% as shown in Figure 8. Except for the age cor-
rection, all the other three factors significantly contribute to the
improvement of the prediction accuracy. Based the analysis of
these factors, we further proposed a novel grading biomarker.
Using the grading biomarker, the prediction accuracy further
increased to 75%. The proposed grading biomarker benefits
not only from the studies of the above pre-processing steps but
also from the use of the sparse representation technique. Due
to the sparsity constraint, the sparse representation technique
can only allow a few similar training subjects from AD and
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TABLE V
RESULTS OF DIFFERENT CLASSIFIERS USING THE COMBINED
BIOMARKERS.
Method ACC SEN SPE AUC
Combined biomarker SVM 77.2% 75.0% 80.1% 84.9%
Combined biomarker RF 80.7% 86.7% 72.6% 87.0%
NC to propagate their disease information to the MCI subjects
for calculating the grading features, thus eliminating some
dissimilar subjects in the feature calculation. The obtained
accuracy using age and cognitive measures is 76%, which is
slight higher than that of the grading biomarker. However,
the prediction accuracy was further boosted to 81% with an
AUC of 87% by combining the proposed grading biomarker
with age and cognitive measures, indicating that there are
complementary information between these different measures.
One contribution of our work is the comprehensive study
of the impact of different factors: (1) We demonstrated that
non-rigid registration with a control spacing point between
5mm and 10mm is a good choice for the classification of AD
using MR intensities as this registration level can provide a
tradeoff between the removal of inter-subject variability and
the amount of detectable pathological changes. However, as
shown in Figure 5, the pathological changes in the ventricle
region was best detected using registration with a 20mm
control point spacing while the highest discriminative power in
the hippocampus area was obtained after applying registration
with a control spacing point between 5mm and 10mm. There-
fore, it may be helpful to apply a multi-level feature selection
to extract the pathological changes at different registration
levels so that the best detectable pathological changes at
different regions can be combined for classification. We will
investigate this in our future work. (2) Since normal aging has
similar atrophy effects on certain regions as AD [20], [25],
[48], it would cause a confounding effect on using the disease-
specific changes for classification. Thus, a linear regression
model [25], [49] was used to remove the confounding effect
of normal aging. Although the improvement by adding age
correction is not significant, it is consistently helpful for all
the classification experiments as shown in Figures 4 and 5.
In addition, it should be noted that the linear correction of
age is an approximation of the normal aging process since
the trajectory of normal aging can be assumed to be nonlinear
as shown in previous studies [21], [50]. A more specialized
nonlinear regression model would be more effective in re-
moving the confounding effects of normal aging. Although
the normal aging effect was removed from the calculation
of disease-specific MR biomarkers, age was added as an
additional feature in the final classification. This is due to
the fact that age is a risk factor for AD. It is reported that
older subjects are more likely to develop AD than younger
subjects. This means that age is an important predictor for
classification of AD. Thus, we added age as an additional
feature in the final classification. (3) Moreover, we observed
that the effectiveness of the feature selection is related to the
accuracy of the registration as demonstrated in Table II. When
affine registration is applied, the anatomies are not aligned well
and thus the feature selection is not effective at this registration
level as it does not compare like with like. When very accurate
registration is applied (i.e. non-rigid registration with a 2.5mm
control point spacing), the feature selection is also not effective
as less noisy features present due to the removal of inter-
subject variability. Feature selection is more effective at the
registration level between 5mm and 10mm since not only the
pathological changes can be detected at this registration level
but also the amount of noisy voxels (possible due to remaining
inter-subject variability) is still large as shown in Figure 5. (4)
In addition, when the classifier is trained on AD vs NC, the
classification performance between PMCI and SMCI can be
significantly improved, which is in accordance with results
presented in previous studies [14], [51], [52]. This finding
is encouraging because it is easier to obtain labeled training
data from AD and NC subjects than from MCI subjects (MCI
subjects need to be tracked for years to establish their training
labels while the training labels of AD and NC subjects can be
determined at baseline).
Another contribution in this work is the proposal of the
global grading biomarker. In contrast to recent studies on the
ADNI data that rely on combinations of complex features [7],
[33], [53], [54], [55] or integrations of multiple modalities
[5], [56], [14], the proposed biomarker is a single MRI-based
interpretable feature. When the grading value is close to −1, it
indicates that the subject is more characteristic of PMCI than
SMCI and has a high possibility to convert to AD within 3
years while the grading value 1 means that this MCI subject
will possibly remain stable within this period. Although the
proposed grading biomarker is calculated using normalized
intensities, it can also be calculated using other features such
as the grey matter density maps [22] or cortical thickness [13].
However, the factors including registration, age correction,
feature selection and training groups may also have significant
influence on these features and need to be studied in order to
calculate an effective grading biomarker for the prediction of
MCI-to-AD conversion.
The prediction accuracy for conversion from MCI to AD
varies in the range of 56%-82% in recent studies as shown in
Table VI. The variations in the reported results can be caused
by several factors such as different machine learning methods,
different biomarkers, different subsets from ADNI, different
cross validations. Another important factor, which can also sig-
nificantly affect the prediction results, is how the MCI subjects
are separated into SMCI and PMCI. For example, as shown
in Table VI, the proposed combined biomarkers achieved
significantly different results when different definitions of
SMCI and PMCI were adopted. Based on the definition as
described in section II-A, the proposed biomarkers achieved
a classification AUC of 87%. When we applied the same
validatation on the subjects using the definition of SMCI and
PMCI as described in [20], the classification AUC increased
to 92%. The improvement is caused by the strict definition of
SMCI as in [20], which removed those SMCI subjects who
converted to AD after 36 months. In spite of the large variation
in the reported accuracies, it is encouraging to note that there
is an increasing trend in the prediction accuracy with the recent
progress on this challenging task, which will finally lead to a
prediction rate suitable for clinical use.
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TABLE VI
RESULTS OF PREVIOUS STUDIES FOR PREDICTING MCI-TO-AD CONVERSION ON THE ADNI DATASET. RF WAS APPLIED TO THE COMBINED
BIOMARKER FOR TRAINING CLASSIFIERS. ACC: ACCURACY; AUC: AREA UNDER THE RECEIVER OPERATING CHARACTERISTIC CURVE.
Study Data Number of Subjects Conversion time ACC AUC
[4] MRI 76 PMCI, 134 SMCI 0-18 months 64% -
[57] MRI 72 PMCI, 50 SMCI 0-24 months 73% -
[3] MRI 27 PMCI, 76 SMCI 0-36 months 81% 77%
[22] MRI 76 PMCI, 134 SMCI 0-18 months 67% -
[33] MRI 167 PMCI, 238 SMCI 0-48 months 56%-68% -
[58] MRI, CSF 69 PMCI, 170 SMCI 0-36 months 62% 73%
[59] MRI 154 PMCI, 215 SMCI 0-36 months 72% -
[9] MRI 62 PMCI, 256 SMCI 0-18 months 66% 65%
[7] MRI 72 PMCI, 131 SMCI 0-18 months 71% -
[23] MRI, age 167 PMCI, 238 SMCI 0-48 months 74% -
[60] MRI, PETcognitive scores 38 PMCI, 50 SMCI 0-24 months 78% 77%
[10] MRIcognitive scores 153 PMCI, 182 SMCI 0-36 months 65% -
[55] MRI 89 PMCI, 111 SMCI 0-36 months 75% 84%
[14] MRI, PETAPOE 47 PMCI, 96 SMCI 0-36 months 74% 80%
[19] MRI 167 PMCI, 238 SMCI 0-48 months 72% 76%
[20] MRI, agecognitive scores 164 PMCI, 100 SMCI 0-36 months 82% 90%
Combined biomarkers
(this study)
MRI, age
cognitive scores
164 PMCI, 100 SMCI 0-36 months 84% 92%
171 PMCI, 129 SMCI 0-36 months 81% 87%
V. CONCLUSION
In this work, we first investigated the influence of four
factors on the prediction of MCI-to-AD conversion: regis-
tration accuracy, age correction, feature selection and the
selection of training data. Furthermore, we have proposed a
new biomarker based on global grading for the prediction of
MCI-to-AD conversion. The evaluation on the ADNI dataset
shows promising results and demonstrates the efficacy of the
proposed biomarker. As indicated by the experimental results,
the improvement of the classification performance on the MCI-
to-AD conversion prediction benefits from the contribution
of several factors: (a) the optimal registration level to align
images to the template space; (b) the removal of the age-
related effect; (c) the feature selection step using EN; (d)
the calculation of the grading biomarker using AD and NC
groups; (e) the use of the sparse representation technique; (f)
the combination of cognitive measures.
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